Bayer Aktiengesellschaft (WSE:BAY)
Poland · Delayed Price · Currency is PLN | Market Cap | 193.63B +66.7% |
| Revenue (ttm) | 195.06B -1.7% |
| Net Income | -7.47B |
| EPS | -7.60 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 9.59 |
| Dividend | 0.47 (0.24%) |
| Ex-Dividend Date | Apr 27, 2026 |
| Volume | 36 |
| Open | 194.45 |
| Previous Close | 190.85 |
| Day's Range | 194.45 - 197.95 |
| 52-Week Range | 113.32 - 230.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and ge... [Read more]
Financial Performance
In 2025, Bayer Aktiengesellschaft's revenue was 45.58 billion, a decrease of -2.21% compared to the previous year's 46.61 billion. Losses were -3.62 billion, 41.8% more than in 2024.
Financial numbers in EUR Financial StatementsNews
Bayer to Present New Cardiac Amyloidosis and Heart Failure Data at the Heart Failure Society of America (HFSA) Annual Scientific Meeting
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that one late-breaking presentation along with five posters across its cardiovascular programs will be featured at the Heart Failur...
Bayer partners with actress Melissa Joan Hart to increase awareness of Lynkuet
Bayer (BAYRY) announced a partnership with actress and menopause advocate Melissa Joan Hart to increase awareness about Lynkuet 60mg capsules, Bayer’s FDA-approved, hormone-free prescription treatment...
Actress and Menopause Advocate Melissa Joan Hart Partners with Bayer to Raise Awareness about Lynkuet® (elinzanetant), a Prescription Treatment for Moderate to Severe Hot Flashes due to Menopause
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced a partnership with actress and menopause advocate Melissa Joan Hart to increase awareness about Lynkuet® (elinzanetant) 60mg capsules, Bayer's FD...
Bayer announces FDA acceptance of Kerendia sNDA
Bayer (BAYRY) announced that the FDA accepted the company’s supplemental new drug application, or sNDA, for Kerendia, which is being investigated for the treatment of adults with chronic kidney diseas...
U.S. FDA Accepts Bayer's Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer announced today that the U.S. Food and Drug Administration (FDA) accepted the company's supplemental New Drug Application (sNDA) for KERENDIA® (fin...
Bayer to Invest $2.2 Billion in U.S. Pharma Manufacturing Expansion
The German company, which said its new site in Ohio will create around 600 jobs, is the latest European drugmaker to invest in the U.S.
Bayer to invest $2.2 billion in new US pharma site
Bayer's pharmaceuticals unit on Friday unveiled plans to invest $2.2 billion in a new manufacturing site in New Albany, Ohio, part of a push to boost the business's US revenue.
Bayer to invest $2.2B in new manufacturing site in New Albany, Ohio
Bayer (BAYRY) announced plans to invest $2.2B in a new pharmaceutical manufacturing site in New Albany, Ohio, U.S. Building on more than $7B in U.S. pharma R&D and manufacturing spend…
Bayer to Invest 2.2 Billion U.S. Dollars in a New Manufacturing Site in the United States
NEW ALBANY, Ohio--(BUSINESS WIRE)--Bayer announced on Friday plans to invest 2.2 billion U.S. dollars in a new pharmaceutical manufacturing site in New Albany, Ohio, U.S. Building on more than seven b...
Alka-Seltzer Plus® to Relaunch as Alka-Seltzer™ Cold in 2026, Bringing Simpler Shopping and More Value to the Cough/Cold Aisle
WHIPPANY, N.J.--(BUSINESS WIRE)--Alka-Seltzer Plus® will relaunch in 2026 as Alka-Seltzer™ Cold, introducing a more intuitive brand architecture, simplified packaging and value-focused options designe...
Bayer faces trial test of remaining Roundup claims after US Supreme Court win
Attorneys for three cancer patients told a Missouri jury on Tuesday that Bayer's Monsanto unit failed to adequately test its Roundup weedkiller before selling it, starting a trial that could help de...
Bayer announces FDA accepts Lynkuet sNDA for Priority Review
Bayer (BAYRY) announced that the U.S. Food and Drug Administration has accepted the company’s supplemental New Drug Application and granted Priority Review designation for Lynkuet under investigation ...
U.S. FDA Accepts sNDA and Grants Priority Review to Bayer's Lynkuet® (elinzanetant) for a New Indication for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Endocrine Therapy Related to Breast Cancer
WHIPPANY, N.J.--(BUSINESS WIRE)--Today Bayer announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) and granted Priority Review ...
Bayer to sell cancer drug Stigvarga for up to $431M, WSJ reports
Bayer (BAYRY) has agreed to sell the rights to its cancer drug Stivarga to Gruenenthal Group for up to EUR 375M, or $431M, The Wall Street Journal’s Adria Calatayud reports.
Bayer Sells Cancer Drug to Gruenenthal for Up to $431 Million
The drug, approved to treat various forms of cancer, is due to lose patent protection in the EU in 2029 and in the U.S. a year later.
Robigo announces Series A funding led by Leaps by Bayer
Robigo announced a Series A funding led by Leaps by Bayer (BAYRY) with participation from Illumina Ventures, SVG Thrive, Congruent Ventures, and Endeavor8. The round will accelerate the commercial lau...
Robigo and Leaps by Bayer Announce Series A Financing to Advance Engineered Biologicals That Protect Yields and Reduce Costs
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Robigo, a biotechnology company engineering no-compromise biological solutions for crop protection, today announced a Series A funding led by Leaps by Bayer with par...
Bayer receives FDA approval for Kerendia for CKD with type 1 diabetes
Bayer (BAYRY) announced that theFDA approved Kerendia to reduce urinary albumin-to-creatinine ratio, which is expected to reduce the risk of sustained estimated glomerular filtration rate decline and ...
Bayer's KERENDIA® (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA® (finerenone) to reduce urinary albumin-to-creatinine ratio (UAC...
Bayer's Monsanto unit urges Missouri judge to approve $7.25 billion Roundup settlement
Bayer's Monsanto unit urged a Missouri judge on Monday to approve its $7.25 billion proposed settlement of lawsuits alleging that its weedkiller Roundup causes cancer, saying there is no other way to...
Bayer faces pivotal test of $7.25 billion Roundup settlement in Missouri court
Bayer's Monsanto unit heads to a Missouri state court on Monday seeking approval of a $7.25 billion settlement that could resolve tens of thousands of U.S. lawsuits alleging that its popular weedkill...
Bayer Launches Nationwide Science Delivers Tour to Take Science on the Road
WHIPPANY, N.J.--(BUSINESS WIRE)--Amid growing concerns over misinformation around health and science, Bayer launched a nationwide tour of its Science Delivers mobile interactive experience. The mobile...
Bayer price target raised to EUR 65 from EUR 60 at HSBC
HSBC analyst Rajesh Kumar raised the firm’s price target on Bayer (BAYRY) to EUR 65 from EUR 60 and keeps a Buy rating on the shares. The firm adjusted targets…
Bayer granted accelerated approval for Hyrnuo by FDA
Bayer (BAYRY) announced that following Priority Review and Breakthrough Therapy Designation, the FDA has granted accelerated approval for Hyrnuo, for the first-line treatment of adult patients with lo...
U.S. FDA Grants Accelerated Approval to Bayer's HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer
WHIPPANY, N.J.--(BUSINESS WIRE)--U.S. FDA Grants Accelerated Approval to Bayer's HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated NSCLC.